Royalty Pharma
RPRX
378 hedge funds and large institutions have $9.49B invested in Royalty Pharma in 2024 Q1 according to their latest regulatory filings, with 64 funds opening new positions, 161 increasing their positions, 114 reducing their positions, and 47 closing their positions.
43% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $10.7M
41% more repeat investments, than reductions
Existing positions increased: 161 | Existing positions reduced: 114
36% more first-time investments, than exits
New positions opened: 64 | Existing positions closed: 47
9% more capital invested
Capital invested by funds: $8.74B → $9.49B (+$748M)
4% more funds holding
Funds holding: 363 → 378 (+15)
0.33% more ownership
Funds ownership: 69.67% → 70% (+0.33%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$90M |
| 2 |
Swedbank
Stockholm,
Sweden
|
+$82.9M |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$78.4M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$60.4M |
| 5 |
NSCM
New South Capital Management
Memphis,
Tennessee
|
+$43.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$70.2M |
| 2 |
Goldman Sachs
New York
|
-$66.8M |
| 3 |
Morgan Stanley
New York
|
-$63M |
| 4 |
SCM
Suvretta Capital Management
New York
|
-$48.3M |
| 5 |
Amundi
Paris,
France
|
-$43.8M |
RPRX Hedge Fund Activity: Q1 2024 in Review
378 of the 6,958 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2024, worth a combined $9.49B — up 8.6% from $8.74B a quarter earlier.
Buyers outnumbered sellers: 64 funds opened new RPRX positions and 47 closed out — a net gain of 17 holders — while 161 added to existing stakes and 114 trimmed.
The largest buyer was Millennium Management, adding an estimated $90M. The largest seller was Man Group, cutting an estimated $70.2M.
- 378 institutional investors held Royalty Pharma (RPRX) as of Q1 2024, up from 363 in Q4 2023.
- Funds reported $9.49B of Royalty Pharma stock for Q1 2024, up 8.6% quarter-over-quarter.
- 64 funds opened new Royalty Pharma positions in Q1 2024 and 47 closed out, a net change of +17 holders.
- The largest Royalty Pharma buyer in Q1 2024 was Millennium Management, an estimated $90M added.
- The largest Royalty Pharma seller in Q1 2024 was Man Group, an estimated $70.2M sold.
Based on aggregated 13F filings for Q1 2024.